Fulgent Genetics, Inc. (NASDAQ: FLGT) reported Q2 EPS of ($0.58), $0.14 worse than the analyst estimate of ($0.44). Revenue for the quarter came in at $85.4 million versus the consensus estimate of $91.77 million.

GUIDANCE:

Fulgent Genetics, Inc. sees FY2026 EPS of ($2.22)-($2.35), versus the consensus of ($1.55). Fulgent Genetics, Inc. sees FY2026 revenue of $330-340 million, versus the consensus of $352.2 million.

For earnings history and earnings-related data on Fulgent Genetics, Inc. (FLGT) click here.